Onyx gives JAK2 back to S*BIO
This article was originally published in Scrip
Executive Summary
Privately-held Singapore company, S*Bio, has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx Pharmaceuticals (US), in what S*Bio describes as a "restructuring" of the collaboration and option agreement that the companies entered into in January 2009.